九强生物(300406) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥410,213,163.82, a slight increase of 0.01% compared to the same period last year, while year-to-date revenue decreased by 7.86% to ¥1,122,220,324.67[7] - Net profit attributable to shareholders for Q3 2022 was ¥106,437,843.04, representing an increase of 18.86% year-on-year, but a decrease of 13.34% year-to-date to ¥269,287,736.49[7] - The net profit excluding non-recurring gains and losses for Q3 2022 was ¥107,113,850.57, up 26.24% year-on-year, while year-to-date it decreased by 12.60% to ¥262,913,103.60[7] - Basic and diluted earnings per share for Q3 2022 were both ¥0.18, reflecting a 20.00% increase year-on-year, but a decrease of 13.21% year-to-date[7] - Total operating revenue for the third quarter was ¥1,122,220,324.67, a decrease of 7.8% from ¥1,217,992,018.60 in the previous year[39] - Net profit for the third quarter was ¥274,663,272.40, down 25.6% from ¥369,275,284.31 in the same period last year[41] - Basic earnings per share for the quarter were ¥0.46, compared to ¥0.53 in the previous year[41] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥257,435,129.92, an increase of 49.36% compared to the previous year[7] - The cash inflow from operating activities for the current period is CNY 1,153,607,280.78, an increase from CNY 1,049,637,191.57 in the previous period, representing a growth of approximately 9.9%[46] - The net cash flow from operating activities is CNY 257,435,129.92, up from CNY 172,353,740.44 in the previous period, indicating a year-over-year increase of about 49.4%[46] - The cash inflow from financing activities totaled CNY 1,247,802,759.73, compared to CNY 768,688,099.02 in the previous period, reflecting a significant increase of approximately 62.2%[48] - The net cash flow from financing activities is CNY 64,343,594.07, down from CNY 396,722,792.41 in the previous period, showing a decline of about 83.8%[48] - The cash outflow from investing activities is CNY 385,956,000.63, a decrease from CNY 880,706,847.59 in the previous period, indicating a reduction of approximately 56.2%[46] - The net cash flow from investing activities is -CNY 377,655,121.59, an improvement from -CNY 873,875,819.54 in the previous period, representing a decrease in cash outflow of about 56.7%[46] - The total cash and cash equivalents at the end of the period is CNY 327,724,701.25, compared to CNY 272,281,804.41 at the end of the previous period, marking an increase of approximately 20.4%[48] Assets and Liabilities - Total assets at the end of Q3 2022 were ¥4,574,014,952.06, a 5.89% increase from the end of the previous year[7] - Total liabilities amounted to ¥1,425,830,268.88, slightly up from ¥1,406,347,264.64 in the previous year[36] - Total equity attributable to shareholders of the parent company reached ¥3,151,216,686.95, an increase from ¥2,874,365,713.69 in the previous year[36] - Non-current assets decreased to RMB 2,497,621,285.09 from RMB 2,578,772,995.50 at the beginning of the year[32] - The company reported cash and cash equivalents of RMB 327,724,701.25 as of September 30, 2022, down from RMB 382,518,753.35 at the beginning of the year[32] - The company’s accounts receivable rose to RMB 987,752,153.84 from RMB 917,342,741.14 at the beginning of the year[32] Shareholder Information - The total number of common shareholders at the end of the reporting period is 17,650[15] - The largest shareholder, China Pharmaceutical Investment Co., Ltd., holds 15.78% of shares, totaling 92,894,887 shares[15] - Liu Xi, a natural person, holds 11.38% of shares, totaling 67,013,676 shares[15] - The top ten shareholders do not have any related party relationships or concerted actions among them[15] Investments and Acquisitions - The company invested RMB 30 million in Beijing Zhongke Natai Technology Co., acquiring a 5.1387% stake[24] - The company acquired an additional 4.45% stake in Fuzhou Maixin Biotechnology Development Co., increasing its ownership from 95.55% to 100% for RMB 131.275 million[27] - A wholly-owned subsidiary, Hunan Jiukang Biotechnology Co., was established with a registered capital of RMB 10 million, completed on September 23, 2022[28] Expenses - The company reported a financial expense of ¥38,461,927.50, significantly higher than ¥7,133,946.48 in the previous year, with interest expenses rising to ¥40,477,847.11[39] - Research and development expenses increased to ¥105,432,967.53, up 20.5% from ¥87,511,158.70 in the previous year[39] - The company experienced a 439.14% increase in financial expenses due to higher interest expenses during the reporting period[11] - Government subsidies recognized during the reporting period amounted to ¥10,451,434.66, an increase of 80.91% compared to the same period last year[11] Share Repurchase and Bonds - The company issued 11.39 million convertible bonds with a total amount of 113,900,000 RMB, which began trading on July 20, 2022[22] - The company repurchased and canceled 142,395 shares, accounting for 0.0242% of the total share capital before cancellation[23] - After the cancellation, the total share capital decreased to 588,841,905 shares[23] - The conversion price for the convertible bonds remains unchanged at 17.63 RMB per share[23] - The company repurchased 1,718,200 shares, accounting for 0.2918% of total share capital, with a total transaction amount of RMB 29,994,076[29] Restricted Shares - The company has a total of 1,358,929 restricted shares, with 388,231 shares released during the reporting period[19] - The company approved the unlocking of 388,231 restricted shares, representing 0.0659% of the total share capital, effective July 15, 2022[24] - The company has a total of 4,128,062 shares held through margin trading by a specific fund[15]